Cancer Immunotherapy Comes of Age
摘要：
Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
展开
DOI：
10.1038/nature10673
被引量：
年份：
2011
Nature
(全网免费下载)
Semantic Scholar
(全网免费下载)
Europe PMC
(全网免费下载)
NCBI
(全网免费下载)
Pubmed Central
(全网免费下载)
ResearchGate
(全网免费下载)
ggdpathway.wustl.edu
(全网免费下载)
download.xuebalib.com
(全网免费下载)
211.144.68.84:9998
(全网免费下载)
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
来源期刊
引用走势
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
